Olympus Discloses a New FDA Warning Letter Over Quality-System Gaps

Olympus Corporation, one of the world's largest makers of endoscopes and other medical devices, disclosed on October 13 that it has received a new FDA warning letter — the company's fourth since 2022. The October 7 letter does not allege a fresh batch of violations. It alleges something quality reviewers tend to find more serious: that Olympus's own responses to violations FDA already found, on inspections already completed, were not good enough.

A response problem, not a new-violation problem

The structure of this letter is what makes it worth a second look. FDA warning letters typically follow directly from Form 483 observations issued at the close of an inspection, citing the violations the inspection found. What Olympus and the trade press covering its disclosure describe instead is a letter about the adequacy of the company's own replies — its corrective and preventive action commitments — to quality-management-system findings FDA had already logged across six sites inspected in the second half of 2025. That distinction matters operationally: a warning letter that says "your CAPA response did not satisfy us" signals FDA views the underlying quality-system gap as still open, months after the company believed it had addressed it. For a company the size of Olympus, with manufacturing spread across Japan, the US and Europe, a response FDA rejects at six sites simultaneously points to a systemic CAPA-process question rather than a single facility's local lapse.

What is, and is not, yet public

Regulatory News has not seen the letter itself. As of this writing it has not been posted to FDA's public Warning Letters database, which routinely lags issuance by weeks, so the specific CFR citations, named observations and site-by-site breakdown are not yet independently verifiable. What is known comes from Olympus's own disclosure, relayed consistently across MassDevice's English-language coverage and the Japanese trade outlets Yakuji Nippo and Monoist: the letter is dated October 7, ties back to six-site inspections run in late 2025, and does not impose a sales restriction, recall order or clearance freeze. Olympus CEO Bob White said in the company's statement, as reported by MassDevice, that Olympus takes FDA's concerns seriously; the company says corrective and preventive actions are already underway and that it plans to provide periodic updates on its progress beyond the initial response.

A recurring compliance thread

• Olympus received three warning letters between November 2022 and March 2023, tied to endoscope manufacturing, reprocessing instructions and quality-system findings at its Tokyo-area and Aizu, Japan facilities.
• FDA placed certain devices made at the company's Aizu, Japan plant under an import alert in 2025 over unresolved quality-system failures — a separate, earlier action from the October 7 letter.
• This letter's trigger — inspections of six sites across three regions in the second half of 2025 — is broader in geographic scope than the company's prior individual-site letters.
• Unresolved warning letters carry FDA's standard consequence for new submissions: the agency can withhold approval of applications or supplements that list a cited facility as a manufacturing site until the warning letter is closed out.

For RA/QA teams tracking supplier and competitor compliance status, the operational question this letter raises is not whether Olympus will eventually close it out — the company says CAPA work has already started — but how long FDA's CAPA review of a six-site response takes, and whether any pending Olympus submissions naming those facilities face a hold in the meantime. Olympus has not said which product lines, if any, are affected beyond the quality-system scope itself.

Frequently asked questions

What did Olympus disclose, and when?

On October 13, 2026, Olympus Corporation disclosed that it received a new FDA warning letter dated October 7, 2026. The letter concerns the adequacy of Olympus's responses to quality-management-system and related-process violations that FDA inspectors logged on Form 483 observations following inspections of six Olympus manufacturing sites in Japan, the United States and Europe conducted in the second half of 2025.

What does the letter actually require?

Olympus says it has already begun corrective and preventive actions and is preparing a formal response to FDA; Japanese trade outlet Yakuji Nippo reports the company intends to submit a comprehensive response within 15 business days of receipt, with periodic updates to follow. The letter does not restrict Olympus's ability to manufacture, sell or distribute its products in the US and does not call for a recall or new clearances, according to MassDevice's reporting of the company's disclosure.

Can I read the letter itself?

Not yet. As of this writing the letter had not been posted to FDA's public Warning Letters database, which typically lags issuance by weeks. Everything reported here traces to Olympus's own disclosure as relayed by MassDevice, Yakuji Nippo, Monoist and Moneypost; Regulatory News has not seen the letter's specific CFR citations and is not asserting any beyond what the company itself has characterized.

Has Olympus had FDA compliance problems before?

Yes. The company received three warning letters between November 2022 and March 2023 tied to endoscope manufacturing, reprocessing and quality-system findings at its Tokyo-area and Aizu facilities, and FDA placed devices made at its Aizu, Japan plant under an import alert in 2025 over unresolved quality-system failures. This October 7 letter is a separate, more recent action tied to 2025 inspection findings at six sites, not a continuation of the import-alert matter as currently reported.